Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO™ Device in Soft Tissue Sarcoma

Status:Active, not recruiting
Age Range:18 - Any
Start Date:December 15, 2016
End Date:December 31, 2019

Use our guide to learn which trials are right for you!

Feasibility of Assessing Drug Response to Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma Patients Undergoing Surgery.

This is a feasibility study in patients with localized or metastatic soft tissue sarcoma
undergoing surgery to determine how sarcoma in situ responds to injected microdoses of
anti-cancer therapeutics.

This is a single arm, pilot study designed to test the feasibility of using the CIVO
(Comparative In Vivo Oncology) system in patients with soft tissue sarcoma accessible for
percutaneous injection. Patients who are scheduled for surgical biopsy or tumor resection
surgery will be injected one to three days prior to surgery using the CIVO device. Minute
volumes (up to 8.3 microliters) of saline (negative control) or microdoses of anti-cancer
agents will be percutaneously injected in a columnar fashion through each of 8 needles into a
single enlarged solid tumor. Following the patient's biopsy surgery or tumor resection
surgery, the injected portion and a small uninjected portion will be used to determine the in
situ drug response in the tumor. None of the data from this evaluation will be shared with
patients or used to make clinical decisions. Study clinicians will have access to the
patient's health record for 1 year after the study to monitor patient treatment responses.
Such information will be used to help evaluate the correlation between clinical response and
tumor response assessed via CIVO.

Inclusion Criteria:

- 18 years of age or over.

- At least one suspected soft tissue sarcoma tumor that is considered by the
investigator to be: (1) accessible for percutaneous injection and (2) at least 2.5 cm
in shortest dimension for patients undergoing an incisional biopsy, or at least 3 cm
in shortest dimension for patients undergoing an excisional biopsy/tumor resection.
Tumors should not be selected if the Investigator believes them to be necrotic or
exhibit signs of radiation-induced fibrosis.

- Prior surgical evaluation and plan for surgical biopsy or surgery to remove the tumor
being injected.

- ECOG performance status of 0-2 (or a Karnofsky performance status of >50%)

- Labs required for enrollment (prior to microinjection):

- Absolute neutrophil count > 1000/mm3

- Platelet count > 50,000/mm3

- Hematocrit > 25%

- Creatinine <3.0 mg/dl

- Total Bilirubin <4.0 mg/dl

- Bilirubin <4.0 mg/dl, SGOT ≤ 1.5 times the upper limit of normal

- PT and PTT ≤ 1.5 times the upper limit of normal

Exclusion Criteria:

- Subjects with active fungal, viral, or bacterial infections.

- Pregnant women.

- Inability to give informed consent.

- Current treatment with anticoagulation such as warfarin or low-molecular-weight

- Tumors near critical structures such as those located near or in the brain or spine.
This assessment will be determined by the treating clinician.
We found this trial at
450 Lakeville Road
Lake Success, New York 10042
Principal Investigator: Gary Deutsch, MPH, MD
Lake Success, NY
Click here to add this to my saved trials
3181 S.W. Sam Jackson Park Road
Portland, Oregon 97239
503 494-7999
Principal Investigator: Kenneth Gundle, MD
OHSU Knight Cancer Institute OHSU Knight Cancer Institute is known worldwide for our contributions to...
Portland, OR
Click here to add this to my saved trials
Seattle, WA
Click here to add this to my saved trials